Date: 2014-05-07
Type of information: Licensing agreement
Compound: Xenomouse® Antibodies and maytansinoid ADC technology for an undisclosed target in HER2-negative breast cancer
Company: Oxford BioTherapeutics (UK) Amgen (USA - CA) Immunogen (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: HER2-negative breast cancer
Details: * On May 7, 2014, Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced that it has obtained the exclusive global rights to certain Xenomouse® antibodies generated by Amgen and to ImmunoGen\'s maytansinoid ADC technology for an undisclosed target. The rights were granted under the existing strategic collaboration between Oxford BioTherapeutics and Amgen. Oxford BioTherapeutics intends to use the antibodies and ADC technology to develop a novel ADC targeting a protein in HER2-negative breast cancer, initially focusing on triple negative breast cancer, and other cancers, where the target is expressed. The target was identified using the Company\'s OGAP® discovery technology. Oxford BioTherapeutics\' pipeline of ADCs is based on novel targets, discovered with its OGAP® technology, combined with proprietary antibody and cancer toxin technologies brought together through a series of collaborations with leading companies in the field. The pipeline incorporates a fully human antibody generated using Amgen\'s Xenomouse® technology, combined with one of ImmunoGen\'s maytansinoid cancer-killing agents, which have been used in a recently approved ADC targeting HER2-positive breast cancer. This novel antibody-based cancer therapy has completed in vivo proof-of-concept in several solid and liquid tumor models and exploratory toxicology testing, and is currently undergoing preparation for an IND application.
Financial terms:
Latest news:
